Latham & Watkins Advises Nalu Medical, Inc. on Acquisition by Boston Scientific

Boston Scientific Corporation (NYSE: BSX) announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain. Boston Scientific has been a strategic investor in Nalu Medical since 2017. The transaction consists of an upfront cash payment of approximately US$533 million for the remaining equity not owned by Boston Scientific.

Latham & Watkins LLP represents Nalu Medical, Inc. in the transaction with a corporate deal team led by Boston partner Hans Brigham and associate Laki Triantafylidis, along with Jennifer Boyd, Sue Kim, and Cherrie Wang. Advice was also provided on capital markets matters by Orange County/Bay Area partners Shayne Kennedy and Ross McAloon, with associates Jacob Walsh, Kennedy Holmes, and Tony Noh; on tax matters by Los Angeles partner Eric Cho, with associate Grace Jang; on compensation and benefits matters by San Diego partner Holly Bauer and Orange County counsel Sara Schlau, with associate Iryna Onyshchenko; on healthcare regulatory matters by Washington, D.C. counsel Nicole Liffrig Molife, with associate Megan Lich; on FDA matters by Washington, D.C. partner Nathan Beaton, with associates Maya Frost-Belansky and Trevor Thompson; on intellectual property matters by San Diego counsel Robert Yeh, with associate Kristina Funahashi; on data privacy and cybersecurity matters by Washington, D.C. partner Marissa Boynton, with associate Kathryn Parsons-Reponte; on antitrust matters by Washington, D.C. partners Mandy Reeves and Patrick English, with associate Nathaniel Amann; and on emerging company and growth matters by associates Eduard Grigoryan and Emma Mayberry.